Cureatr is a technology company.
Cureatr has raised $9.0M across 2 funding rounds.
Cureatr has raised $9.0M in total across 2 funding rounds.
Cureatr has raised $9.0M in total across 2 funding rounds.
Cureatr's investors include Activate Venture Partners, Primetime Partners, F-Prime Capital Partners.
Cureatr has raised $9.0M across 2 funding rounds. Most recently, it raised $3.0M Venture Round in June 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2018 | $3.0M Venture Round | Activate Venture Partners, Primetime Partners | |
| Oct 1, 2013 | $6.0M Series A | F-Prime Capital Partners |
Cureatr is a healthcare technology company that builds a comprehensive medication management (CMM) platform to address suboptimal medication use, estimated at a $528 billion problem in the US. It provides real-time medication lists for prescribers, alerts for issues like therapeutic duplication or non-adherence, and notifications for care managers on patient pickups, while offering clinical services via board-approved pharmacists for complex cases[1][3]. The platform serves payers, health systems, and healthcare providers, solving medication reconciliation, patient engagement, and readmission risks to improve adherence and outcomes[1][2][3]. With around 54-245 employees and $11.3 million in revenue, Cureatr demonstrates steady growth as a New York-based firm founded in 2011[3][5].
Cureatr was founded in 2011 in New York City, emerging from a recognition of fragmented care coordination and medication errors plaguing healthcare[1][3][5]. The founders leveraged expertise in healthcare data and technology to create a mobile solution aimed at removing barriers to communication between providers and patients[2]. Early focus centered on pharmacist-led interventions and tech-enabled reconciliation, gaining traction by partnering with health systems and payers to demonstrate reduced readmissions and better quality metrics[1][3]. This evolution positioned Cureatr as a hybrid clinical-tech provider, scaling from software to full-service medication management[4][5].
Cureatr rides the wave of value-based care and digital health transformation, where payers and providers prioritize outcomes over volume amid rising chronic disease burdens. Timing aligns with post-pandemic emphasis on remote coordination and AI-driven insights, amplified by regulatory pushes like CMS readmission penalties[1]. Market forces favoring it include exploding healthcare data volumes, pharmacist shortages, and a shift to preventive medication management, positioning Cureatr to influence ecosystems by enabling scalable, tech-pharmacist hybrids that lower costs and improve equity in access[3][4]. It contributes to a broader trend of healthtech firms bridging silos, akin to competitors like Sharecare or WellSky, but with a sharp CMM focus[1].
Cureatr is poised for expansion through AI enhancements to its platform, deeper payer integrations, and potential acquisitions amplifying its pharmacist network amid growing demand for personalized med management. Trends like precision medicine and telepharmacy will accelerate its trajectory, potentially evolving it into a dominant CMM leader as health systems consolidate tech stacks. Watch for partnerships scaling its $528B mission, solidifying its role from niche solver to ecosystem shaper—echoing its founding promise to make medications safe and effective for all[3].